Company
Headquarters: Beijing, China
Employees: 907
CN¥7.92 Billion
CNY as of Jan. 1, 2026
US$1.13 Billion
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $222.61 B |
| Danaher | $164.98 B |
| Siemens Healthineers AG | $57.84 B |
| IDEXX Laboratories, Inc. | $53.62 B |
| Lonza Group Ltd | $47.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.43 B |
| EBITDA | CN¥577.0 M |
| Gross Profit TTM | CN¥1.14 B |
| Profit Margin | 30.12% |
| Operating Margin | 40.37% |
| Quarterly Revenue Growth | -17.40% |
Beijing Strong Biotechnologies, Inc. has the following listings and related stock indices.
Stock: SZSE: 300406 wb_incandescent